Gilead acquiring Nimbus' NASH subsidiary

Gilead Sciences Inc. (NASDAQ:GILD) is acquiring the Nimbus Apollo Inc. subsidiary of Nimbus Therapeutics LLC (Cambridge, Mass.) for $400 million up front and up to $800 million in

Read the full 284 word article

User Sign In